主催: The Japanese Pharmacological Society, The Japanese Society of Clinical Pharmacology
会議名: WCP2018 (18th World Congress of Basic and Clinical Pharmacology)
開催地: Kyoto
開催日: 2018/07/01 - 2018/07/06
Background: Artesunate/Amodiaquine is used as an ACT in treating malaria, and are metabolized into their more active forms by the CYP450 enzyme. Anthropogenic utilization of Cadmium has increased its environmental pollution over the years especially in developing countries, some of which are malaria endemic. Cadmium has been reported to inhibit CYP450 enzyme in vitro. This study was designed to evaluate the effect of chronic cadmium exposure on the curative antimalarial activity of Artesunate/Amodiaquinein vivo.
Method: Forty-two (42) male swiss mice were intraperitoneally injected with varying doses (0, 0.25, 0.5, 1.0, 2.0 mg/Kg body weight) of Cadmium chloride once daily for 28 days. The mice were inoculated intraperitonealy with 10^7chloroquine resistant Plasmodium berghei ANKA strain a day after the last admistration of Cadmium. The standard curative antimalarial test was employed to assess the parasitological activity and survival rates were assessed over 28days.
Result: Cadmium chloride at 0.25mg/Kg dose showed a statistically significant (p<0.004) decrease in Artesunate/ Amodiaquine parasite clearance time when compared with the positive control. There was no significant difference in survival rate across all groups, though there was a remarkable reduction in survival time at low dose (0.25mg/Kg).
Conclusion: Cadmium appears to have worsened the disease progression in the absence of treatment but did speed up cure in the presence of Artesunate/Amodiaquine.
